1. S-ICD sales are going through the roof this quarter as they have fixed their supply shortfall issues.
2. The renal denervation device BSX has is a lot better than MDT device that failed trial and BSX will have market to itself.
3. Buyout in the works.
I would take any or all three!!!!!!!!! Could this go to $20? Never in my wildest dreams did I think this would ever happen last year:))))